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Abstract The immunosuppressant cyclosporin A (CsA) reduced
the functional expression of Kir2.1 potassium channels in
Xenopus oocytes in a dose-dependent manner with an IC50 of
11 WM when the oocytes were incubated with CsA after RNA
injection. FK506 was less effective than CsA; cyclosporin H, a
non-immunosuppressive derivative of CsA, did not have a
significant effect. CsA did not impair protein synthesis since
other potassium channel types (Kir1.1, Kv1.1, Kv1.4) were much
less sensitive to CsA. Our results suggest that the functional
expression of Kir2.1 channels is facilitated by the peptidyl-prolyl
isomerase cyclophilin. The observations illustrate a new role of
CsA in regulation of membrane ion transport, and may provide
an alternative explanation for CsA-induced side effects in clinical
use.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The primary amino acid structures of various ion channel
subunits are now known, however, their transmembrane top-
ologies have not been well de¢ned. Neither is it known how
these subunits are folded, assembled, and inserted into the cell
membranes. As in other proteins, enzymes may participate as
catalysts in the folding of channel-forming proteins [1]. For
example, the cis-trans isomerization of prolyl peptide bonds is
known to be a critical step in the folding of several proteins
[2,3]. Thus, this process may also be important for the assem-
bly of functional ion channel complexes. Cis-trans isomeriza-
tion is a slow process, often acting as a rate-limiting step in
protein folding, but it can be greatly accelerated by peptidyl-
prolyl isomerases [4]. Two principal classes of the isomerases
belonging to the cyclophilin (CyP) and FK506-binding pro-
tein (FKBP) families are now well characterized [5^8]. CyPs
have been directly implicated in the folding of several proteins
and peptides [5,9,10].
In addition to their roles in protein folding acting as pep-
tidyl-prolyl isomerases, CyP and FKBP are also targets of two
powerful immunosuppressant drugs, cyclosporin A (CsA) and
FK506, respectively. CsA is clinically used to prevent graft
rejection after organ transplantation. CsA and FK506 are
thought to induce the immunosuppressant e¡ects by forming
CyP-CsA and FKBP-FK506 complexes, which in turn inhibit
the Ca2-dependent phosphatase calcineurin [11]. While the
calcineurin-mediated pathways of the CsA and FK506 actions
are inhibited by the immunosuppressants at low concentra-
tions (5^100 nM and 0.5^10 nM, respectively [11]), much
higher concentrations are needed to inhibit the potency of
CyP or FKBP to act as peptidyl-prolyl isomerases (1^10
WM [4]).
It was recently shown that CsA signi¢cantly reduces the
surface expression in Xenopus oocytes of homo-oligomeric
K7 neuronal nicotinic and type 3 serotonin (5HT3) receptors,
suggesting that the peptidyl-prolyl isomerase CyP is critically
involved in the expression of these proteins [12,13]. CsA also
inhibits apical secretory K channels in rabbit cortical collect-
ing tubule principal cells [14]. Many potassium channel pro-
teins show proline-rich regions, which may be a¡ected by the
peptidyl-prolyl isomerases. The inward recti¢er potassium
channel Kir2.1 (IRK1), for example, contains 12 proline res-
idues in the C-terminal domain and one proline in the core
domain (M1, P-domain, and M2) [15]. We therefore hypothe-
sized that peptidyl-prolyl isomerases may be involved in the
functional expression of potassium channels. We examined
whether Kir2.1 potassium channel expression is dependent
on the activities of the peptidyl-prolyl isomerases by using
CsA and FK506 as selective blockers of CyP and FKBP,
respectively. We report here that CsA speci¢cally reduces
the functional expression of the Kir2.1 channels in Xenopus
oocytes without in£uencing the electrophysiological properties
of the expressed channels. The results indicate that neither a
simple block of functional channels, a block of protein syn-
thesis nor an inhibition of general posttranslational modi¢ca-
tion accounts for the e¡ect of CsA to selectively inhibit Kir2.1
channel expression. The functional expression of Kir2.1 chan-
nels may involve CyP as peptidyl-prolyl isomerase or as mo-
lecular chaperone without involving a calcineurin-dependent
pathway.
2. Materials and methods
2.1. Oocyte expression and solutions
Stage V oocytes were surgically obtained from Xenopus laevis anes-
thetized with 0.2% tricaine in ice water. Oocytes were injected with
50 nl (0.05^0.5 Wg/Wl) of RNAs encoding various potassium channel
types as described [16]. Subsequently, oocytes were divided into con-
trol and experimental groups, each containing at least 10 cells. These
groups of oocytes were incubated at 18‡C in Barth’s medium with or
without various concentrations of immunosuppressant drugs. When
the expression of Kir1.1 channels was assayed, Kir1.1 and control
(Kir2.1) oocytes were incubated in modi¢ed Barth’s medium with
increased K concentration (20 mM KCl and 69 mM NaCl instead
of 1 mM KCl and 88 mM NaCl), which increased the survival rate of
oocytes injected with Kir1.1 RNA. CsA was purchased from Sigma
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(St. Louis, MO, USA), cyclosporin H (CsH) was a gift from Dr. G.
Fischer (Max Planck Society, Halle, Germany), and FK506 was
kindly provided by Fujisawa GmbH (Munich, Germany). From a
stock solution of 4 mM (CsA in methanol:ethanol (1:1); CsH in
methanol; FK506 in ethanol), immunosuppressants were added to
the Barth’s medium immediately after injection. Equivalent amounts
of vehicle alone had no e¡ects on channel expression. Whole-oocyte
currents were recorded about 16 h after injection. Extracellular solu-
tions for the recording of the Kir1.1 and Kir2.1 channel currents
contained (in mM): 90 KCl, 3 MgCl2, 10 HEPES (pH 7.2 with
KOH). For other potassium channels, the bath solution contained:
107 NaCl, 10 KCl, 1.8 CaCl2, 10 HEPES (pH 7.2 with NaOH).
2.2. Generation of channel mutants
Point mutants in Kir2.1 channels were created by means of the
Sculptor Kit (Amersham, Buckinghamshire, UK) using oligonucleo-
tide DNA primers and single-stranded template DNA. The mutations
were con¢rmed by sequencing the primer and the surrounding re-
gions. To avoid unexpected mutations, two independent mutant
clones were con¢rmed to have identical electrophysiological proper-
ties. Plasmid DNA was linearized and capped RNA was synthesized
in vitro using commercially available kits (Ambion, Austin, TX,
USA). RNAs encoding Kir2.1 mutants and the other channel types
were generated with the following combinations of linearization en-
zyme and promoter: Kir2.1 and Kir2.1 mutants (XhoI, T3); Kir1.1
(GenBank accession number X72341) (MluI, SP6); rKv1.1 (accession
number X12589) (PstI, T7), rKv1.4 (accession number X16002) (SalI,
SP6).
2.3. Electrophysiological recording and data analysis
Recording of whole-oocyte currents was performed at room tem-
perature (19^22‡C) with a two-electrode voltage clamp ampli¢er (Tur-
bo Tec 10CD, npi electronic, Tamm, Germany). Electrodes were ¢lled
with 2 M KCl and had resistances of 0.6^1.0 M6. Data were collected
with the Pulse+PulseFit acquisition package (HEKA Elektronik,
Lambrecht, Germany) running on an Apple Macintosh Quadra 650
computer. Statistical data are given as mean þ S.E.M. (N = number of
oocytes; n = number of oocyte batches) unless stated otherwise.
In most cases, currents in oocytes expressing Kir2.1 or Kir1.1 chan-
nels were measured by using voltage ramps from +50 mV to 3100 mV
(300 ms) from a holding potential of 0 mV; the current value at 3100
mV was taken as the measured signal, while the current at +50 mV
was used for linear leakage correction for Kir2.1. For Kir1.1, leak
correction was performed by replacing K by Cs in the bath solu-
tion; the current level at 3100 mV obtained in Cs solution was
considered leakage current. For other potassium channels, the holding
potential was 390 mV and a P/6 method with a leak holding potential
of 390 mV and a leak scaling factor of 30.2 was used to subtract leak
and capacitive currents. Peak current was determined at +50 mV. Due
to the large scatter of the data, each experiment included a control
group of oocytes from the same batch injected with Kir2.1 RNA in
the absence and the presence of the corresponding concentration of
immunosuppressant, i.e. the e¡ect of CsA on various potassium chan-
nel types was measured with respect to Kir2.1, the e¡ect of various
drugs with respect to CsA.
The concentration-response curve of the CsA e¡ect was described
according to f= (1+[CsA]h/IC50h)31 where h is the Hill coe⁄cient, f is
the fractional inhibition at various concentrations of CsA, [CsA], and
IC50 provides a measure for the half-maximal inhibition concentra-
tion.
3. Results and discussion
3.1. CsA reduces the expression of functional Kir2.1 channels
To test the e¡ect of CsA on the expression of Kir2.1 chan-
nels, two groups of oocytes were incubated in Barth’s medium
in the presence (experimental groups) and absence (control
group) of various concentrations (0.1^50 WM) of CsA imme-
diately after RNA injection. Channel expression was assayed
by recording whole-oocyte currents using two-electrode volt-
age-clamp techniques. As shown in Fig. 1A, oocytes incubated
in CsA showed smaller potassium currents through the Kir2.1
channels, but did not change the inward rectifying behavior,
which re£ects the channel blockage by Mg2 and spermine
[17,18]. Acute application of 20 WM CsA for about 1 h to
oocytes expressing Kir2.1 channels failed to decrease the in-
ward potassium currents (not shown), indicating that CsA did
not block the functional channels but rather inhibited a proc-
ess involved in channel formation.
CsA reduced the current amplitudes through the Kir2.1
channels in a dose-dependent manner. The data shown in
Fig. 1B were obtained from 63 di¡erent batches of oocytes,
each with about 30 cells. Each data point is a mean value of
whole-oocyte currents at 3100 mV normalized by the respec-
tive control values, representing the expression level of Kir2.1
channels in the presence of the indicated concentrations of
CsA (n is indicated for each data point). A dose-response ¢t
with a Hill coe⁄cient of h = 1 yielded an IC50 estimate of 10.7
WM. This concentration dependence of the CsA action on
Kir2.1 is similar to the e¡ects of CsA on the expression of
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Fig. 1. CsA reduces the expression of functional Kir2.1 channels in Xenopus oocytes. A: Whole-oocyte currents in response to voltage ramps
(300 ms) were measured under two-electrode voltage clamp approximately 16 h after RNA injection. Mean current traces from 21 control oo-
cytes (solid curves) and mean current traces from 22 oocytes which were incubated in Barth’s medium containing 20 WM CsA (dashed curves)
immediately after RNA injection are compared. In addition, the S.E.M. values are shown indicating the variability of current within one batch
of oocytes. Linear leak correction was performed assuming that the current at +50 mV was leakage current with a reversal potential of 0 mV.
B: CsA reduces the Kir2.1 channel expression in a dose-dependent manner. The curve is the result of a dose-response ¢t with a Hill coe⁄cient
of h = 1, yielding an IC50 value of 10.7 WM. Each point represents the remaining current level in the presence of the indicated concentration of
CsA. The number of oocyte batches used to determine the data points are indicated; for each batch at least 20 oocytes were used.
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K7 and 5HT3 receptors in oocytes [12]. The e¡ect in this con-
centration range (WM range), based on previous studies of
collagen triple-helix formation [19], the folding of transferrin
[20], and T-cell signalling [21], suggests a direct inhibition of
the activity of endogenous CyP involved in protein folding.
The e¡ect of CsA mediated by inhibition of calcineurin is
reported to be e¡ective at lower concentrations (6 100 nM)
[11]. The variability of the CsA e¡ect among di¡erent batches
of oocytes might be caused by the variability of endogenous
[CyP] which has been estimated to be in the range of 10^30
WM [21].
3.2. The e¡ects of CsH and FK506 on the expression of Kir2.1
channels
It is known that CsA inhibits the T-cell receptor signal
transduction pathway via the formation of CsA-CyP com-
plexes which inhibit calcineurin [11,22]. To investigate the
possible role played by the known intracellular targets of
CsA, CyP and calcineurin, the e¡ect of a non-immunosup-
pressive derivative of CsA, cyclosporin H (CsH), on the ex-
pression of Kir2.1 channels was examined. Although similar
to CsA in structure, CsH does not inhibit the prolyl isomer-
ases and it does not complex with CyP to inhibit calcineurin
[23]. Incubation of injected oocytes in 20 WM CsH for 16 h
failed to cause a signi¢cant reduction of currents (Fig. 2A),
indicating that CsH does not in£uence channel expression.
This result supports the notion that CsA does not exert its
e¡ect in a non-speci¢c manner.
Two classes of prolyl isomerases, CyP and FKBP, are in-
volved in cellular cis-trans isomerization of prolyl peptide
bonds [5^8]. To examine which class of prolyl isomerases is
involved, we studied the e¡ect of FK506 on Kir2.1 channel
expression. FK506 is about 10 times more potent than CsA
against its cognate isomerase FKBP [11], which, however, is
not abundantly expressed in stage V^VI oocytes of Xenopus
laevis [24]. Consistent with these expectations, 20 WM FK506
induced a smaller e¡ect than CsA (Fig. 2A).
3.3. CsA does not block protein synthesis and processing
The CsA-induced reduction of channel expression might
result from a non-speci¢c blockade of protein synthesis in
oocytes. According to this hypothesis, a non-speci¢c e¡ect
of CsA on protein synthesis in oocytes should cause the block-
ade of expression of any RNA injected. Thus, we examined
how CsA a¡ected other potassium channel proteins and found
that CsA (20 WM) failed to a¡ect functional expression of the
Kv1.1 and Kv1.4 channels (Fig. 2B). These channels are acti-
vated by membrane depolarization and generate outwardly
rectifying potassium currents. Electrophysiological channel
properties such as activation and inactivation kinetics and
voltage dependence of activation of these channels were not
altered (data now shown). Expression of the inward recti¢er
channel Kir1.1 which is expressed in kidney was not signi¢-
cantly a¡ected by 20 WM CsA (Fig. 2B). At higher concen-
trations a small reduction of expression was observed (not
shown). These results indicate that the process of protein
translation leading to Kir2.1 channels is not suppressed via
the inhibition of CyP activity by CsA. Similar results were
obtained by Helekar et al. [12] showing that the expression
FEBS 19796 5-2-98
Table 1
E¡ects of CsA on Kir2.1 mutants
Mutant [CsA] Rel. current (%) N Rel. current (%) N
(WM) (wild type) (mutant)
Y242F 10 62 þ 12 17 59 þ 7 41
20 21 þ 5 26 27 þ 5 23
Y366F 10 44 þ 6 35 57 þ 11 39
10 62 þ 12 27 43 þ 11 23
S3A 30 37 þ 8 28 29 þ 7 31
T3A 30 37 þ 8 28 35 þ 8 30
S357A 30 37 þ 8 28 35 þ 6 20
T383A 30 37 þ 8 28 22 þ 5 29
S426N 20 54 þ 12 24 48 þ 8 26
The remaining current level þ S.D. is listed for the indicated concentrations of CsA and the Kir2.1 mutants. For comparison, the e¡ect on wild type
Kir2.1 channels, obtained in the same batch of oocytes, is included. N indicates the total number of oocytes used.
Fig. 2. A: E¡ects of CsH and FK506 on the expression of Kir2.1
channels. The e¡ects of 20 WM CsH and FK506 on Kir2.1 channel
expression are compared (in identical batches of oocytes) with the
e¡ect of 20 WM CsA (open bars). n indicates the number of batches
and N the total number of oocytes. The error bars are estimates for
the standard error of the mean. B: E¡ects of 20 WM CsA on the ex-
pression levels of Kir1.1, rKv1.1, and rKv1.4 channels, compared
with the expression of Kir2.1.
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of hetero-oligomeric nicotinic receptors was not a¡ected by
CsA. Therefore, the CsA-mediated blockade of CyP activity
is likely to speci¢cally interfere with the process of Kir2.1
channel folding and insertion into the membrane or with oth-
er speci¢c posttranslational mechanisms.
As proline residues are expected to be targets for peptidyl-
prolyl isomerases and as they might constitute parts of inter-
action sites, we generated a double mutant in which two pro-
line residues in a PxxP motif were replaced by alanine,
Kir2.1:P351AWP354A. This mutation, however, did not elimi-
nate the CsA e¡ect (20 WM CsA reduced the expression to
54 þ 7.5% (n = 5, N = 97) while in the same batches of oocytes
expression of wild type Kir2.1 was reduced to 57 þ 7.9%
(n = 5, N = 78)). However, these experiments do not rule out
the possibility that other proline residues play a role as parts
of interaction sites. Interestingly, CsA has a signi¢cantly
weaker e¡ect on the expression of Kir1.1 channels which
share a similar structure of two membrane-spanning segments
with Kir2.1 (40% amino acid identity). In the C-terminal part
of the Kir2.1 polypeptide there are four more proline residues
compared with Kir1.1. Therefore, it is conceivable that the
di¡erent distribution of prolines in the C-terminal polypeptide
parts might result in the di¡erent CsA e¡ects on channel ex-
pression; the potential role of proline residues for the CsA
e¡ect needs to be elucidated by further site-directed mutagen-
esis of Kir2.1.
It is possible that CsA regulates Kir2.1 indirectly by a¡ect-
ing a cellular regulatory protein which in turn a¡ects the
channel. Kir2.1 contains several putative phosphorylation
sites and the phosphorylation states of the channel may be
important in the functional expression. To determine whether
the CsA e¡ect was mediated by the activities of endogenous
tyrosine kinases, protein kinase A (PKA) or protein kinase C
(PKC), we generated several mutants eliminating the two pu-
tative tyrosine phosphorylation sites (Y242F, Y366F) or sev-
eral PKA/PKC sites (S3A, T6A, S357A, T383A, S426N).
None of these mutations changed the channel sensitivity to
CsA signi¢cantly (see Table 1).
CsA is a cyclic peptide widely used in the prevention and
treatment of organ transplant rejection, but with many severe
side e¡ects. Previous studies suggested that CsA may interfere
with ion transport through cell membranes [25,26]. Therefore,
the side e¡ects of CsA may be mediated by ion channels, in
particular by Kir2.1 as shown in this study. This side e¡ect of
CsA could involve multiple organs since potassium channels
of the Kir2 subfamily are expressed in several human tissues
(skeletal muscle, heart, brain, kidney [27]) and they play im-
portant roles in setting the resting membrane potential, bu¡-
ering external K, and modulating action potential wave-
forms [28]. It is noteworthy that the apparent IC50 value of
about 10 WM for the reduction of Kir2.1 expression by CsA is
similar to the concentration of CsA clinically used in organ
transplant recipients. Considering that the inward recti¢er
channels are implicated in numerous cellular functions, it is
possible that the inhibition of Kir2.1 channel expression by
CsA may underlie some of the side e¡ects of CsA in clinical
use.
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